Výsledky vyhledávání - "Chandra Miduturu"

Supplementary Figures S1 - S6, Tables S1 - S2 from First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

Autor: Timothy Guzi, Nancy E. Kohl, Christoph Lengauer, Christopher Winter, Adam Shutes, Natasja Brooijmans, Brian Hodous, Joseph L. Kim, Neil Bifulco, Nicolas Stransky, Weifan Weng, Nooreen Rubin, Michael Sheets, Chandra Miduturu, Margit Hagel

Supplementary Figure S1. Potency against FGFR family and kinome selectivity. Supplementary Figure S2. Kinases with a cysteine at the equivalent position to Cys552 in FGFR4. Supplementary Figure S3. MALDI Mass Spectrometry of FGFR4. Supplementary Figu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8961190ae57361a2b45e2b8293c97f7
https://doi.org/10.1158/2159-8290.22530420

Zobrazit plný text záznamu

Supplementary Methods, Figure Legends from First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

Supplementary Methods and Figure Legends

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0bdbee434896ada0f2bffee6775eee2
https://doi.org/10.1158/2159-8290.22530417

Zobrazit plný text záznamu

Abstract 1717: MAP4K1 inhibition enhances immune cell activation and anti-tumor immunity in preclinical tumor models

Publikováno v: Cancer Research. 81:1717-1717

Hematopoietic progenitor kinase 1 (HPK1, MAP4K1) is a serine/threonine kinase that has been demonstrated to have suppressive effects across a range of immune cells, including T cells and dendritic cells. Loss of MAP4K1 kinase activity is sufficient t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0eb54e4cfffcf5824710a2a61ff8ed1c
https://doi.org/10.1158/1538-7445.am2021-1717

Zobrazit plný text záznamu

The Evolution of Selective FGFR4 Inhibitors for FGF19-Driven Malignancies

Autor: Klaus P. Hoeflich, Timothy J. Guzi, Chandra Miduturu, Megan A. Hatlen, Joseph L. Kim

Publikováno v: 2018 Medicinal Chemistry Reviews ISBN: 9780996293266
2018 Medicinal Chemistry Reviews

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6edc786e55b973d4db9d8ee44b5ec725
https://doi.org/10.29200/acsmedchemrev-v53.ch12

Zobrazit plný text záznamu

Abstract A118: Identification of resistance mechanisms to FGFR4 targeted therapy in hepatocellular carcinoma

Autor: Beni B. Wolf, Cori-Ann Sherwin, Natasja Brooijmans, Christoph Lengauer, Hongliang Shi, Megan A. Hatlen, Michael Sheets, Neil Bifulco, Emily Rozsahegyi, Chandra Miduturu, Yoon-Koo Kang, Marion Dorsch, Richard D. Kim, Nooreen Rubin, Klaus P. Hoeflich, Oleg Schmidt-Kittler, Andy Boral, Joseph L. Kim, Timothy J. Guzi

Publikováno v: Molecular Cancer Therapeutics. 18:A118-A118

When on-target resistance mutations occur in response to potent and selective therapeutics, the target is often considered a validated driver of disease. Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide whose drivers re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::705d66d87fd0d1bda277b4d4b0bd2564
https://doi.org/10.1158/1535-7163.targ-19-a118

Zobrazit plný text záznamu

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

Autor: Christopher Winter, Neil Bifulco, Adam Shutes, Weifan Weng, Michael Sheets, Timothy J. Guzi, Margit Hagel, Chandra Miduturu, Brian L. Hodous, Natasja Brooijmans, Christoph Lengauer, Nicolas Stransky, Nooreen Rubin, Nancy E. Kohl, Joseph L. Kim

Publikováno v: Cancer discovery. 5(4)

Aberrant signaling through the fibroblast growth factor 19 (FGF19)/fibroblast growth factor receptor 4 (FGFR 4) signaling complex has been shown to cause hepatocellular carcinoma (HCC) in mice and has been implicated to play a similar role in humans.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdc7a28fe74bf159b571a83b870c9679
https://pubmed.ncbi.nlm.nih.gov/25847957

Zobrazit plný text záznamu

Abstract LB-324: First isoform selective inhibitor of FGFR4 for the treatment of genomically defined patients with hepatocellular carcinoma

Autor: Lucian Dipietro, Natasja Brooijmans, Christoph Lengauer, Weifan Weng, Joseph Kim, Nicolas Stransky, Timothy J. Guzi, Nooreen Rubin, Margit Hagel, Christopher Winter, Neil Bifulco, Mike Sheets, Chandra Miduturu

Publikováno v: Cancer Research. 74:LB-324

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. Chemotherapy has proven ineffective, and Sorafenib remains the only approved targeted drug with no second or third line treatment options. Sorafenib slows the growt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e4a797ba4bbf8b4b77eeec66e2ebf5a7
https://doi.org/10.1158/1538-7445.am2014-lb-324

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání